|
WO2021030778A1
|
|
Linkage modified oligomeric compounds and uses thereof
|
|
WO2021030763A1
|
|
Modified oligomeric compounds and uses thereof
|
|
WO2021021673A1
|
|
Compounds and methods for modulating gfap
|
|
WO2020243292A1
|
|
Compounds and methods for reducing fus expression
|
|
WO2020236755A2
|
|
Angiotensin ii type 1 receptor targeted oligonucleotides and uses thereof
|
|
WO2020236618A1
|
|
Synthesis of oligomeric compounds comprising phosphorothioate diester and phosphate diester linkages
|
|
WO2020205463A1
|
|
Compounds and methods for modulating ube3a-ats
|
|
WO2020190740A1
|
|
Compounds and methods for reducing kcnt1 expression
|
|
US2020277604A1
|
|
Modulators of malat1 expression
|
|
WO2020172559A1
|
|
Compounds and methods for reducing atxn3 expression
|
|
US2021123059A1
|
|
Modulators of yap1 expression
|
|
WO2020160163A1
|
|
Compounds and methods for reducing app expression
|
|
WO2020132564A1
|
|
Modulators of hsd17b13 expression
|
|
WO2020132558A1
|
|
Compounds and methods for reducing pmp22 expression
|
|
WO2020106996A1
|
|
Compounds and methods for reducing prion expression
|
|
WO2020102630A1
|
|
Modulators of irf5 expression
|
|
TW202028222A
|
|
Modulators of foxp3 expression
|
|
WO2020072991A1
|
|
Modified oligomeric compounds and uses thereof
|
|
WO2020072887A1
|
|
Oligonucleotide mediated no-go decay
|
|
WO2020072883A1
|
|
Chirally enriched oligomeric compounds
|
